Secretome Therapeutics is a clinical-stage biotechnology company (formerly NeoProgen, founded 2018) developing allogeneic, off-the-shelf regenerative therapies derived from neonatal cardiac progenitor cells (nCPCs). Its lead candidate STM-01, and the cell-free secretome STM-2, target heart failure with preserved ejection fraction (HFpEF), dilated cardiomyopathy (DCM) and Duchenne muscular dystrophy associated cardiomyopathy, and are in Phase 1 clinical study. The company publishes a corporate and investor-relations website covering its science, pipeline, team, patient/expanded-access policy and press releases; it publishes no developer program, API, SDK or machine-readable contract of any kind.
Secretome Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Therapeutics, Regenerative Medicine, and Cell Therapy.
Secretome Therapeutics’ developer surface includes product news and 9 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.